Evidence map›Paper›PMID 32773010›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2020

[Progress of Immunotherapy Mechanisms and Current Evidence of PD-1/PD-L1 
Checkpoint Inhibitors for Non-small Cell Lung Cancer with Brain Metastasis].

Jiamin Sheng, Xiaoqing Yu, Hui Li, Yun Fan

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Jiamin ShengWenzhou Medical University, Wenzhou 325035, China.
Xiaoqing YuInstitute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou 310022, China.
Hui LiInstitute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou 310022, China.
Yun FanInstitute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou 310022, China.
Cancer Hospital of Chinese Academy of Medical Sciences · CNChinese Academy of Sciences · CNUniversity of Chinese Academy of Sciences · CNWenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brain metastasis (BM) is a common complication in non-small cell lung cancer (NSCLC), which associates with poor prognosis. Recently, immune checkpoint inhibitors (ICIs) has revolutionized the treatment of tumors. Programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors could produce antitumor effect by activating the autoimmune system. The immunotherapy has already show to have a promising outcome for NSCLC patients with BM, while its specific curative effect and the most ideal mode of the treatment remain to be explored. Here we reviewed the tumor microenvironment (TME) in BM lesions and summarized the role of PD-1/PD-L1 inhibitors in cerebral and its current status in clinical studies.
.

Indexed as

B7-H1 AntigenBrain NeoplasmsCarcinoma, Non-Small-Cell LungHumansImmune Checkpoint InhibitorsImmunotherapyLung NeoplasmsProgrammed Cell Death 1 ReceptorB7-H1 AntigenImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorBrain metastasisImmunotherapyLung neoplasmsPD-1/PD-L1

Identifiers

PMID32773010
PMCPMC7679223
OpenAlexW3049483653

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.